Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) were down 6.7% on Tuesday . The company traded as low as $3.33 and last traded at $3.36, with a volume of 53,436 shares changing hands. The stock had previously closed at $3.60.

A number of analysts have recently weighed in on AUPH shares. Leerink Swann restated an “outperform” rating and issued a $7.00 price target on shares of Aurinia Pharmaceuticals in a report on Wednesday, July 6th. HC Wainwright started coverage on shares of Aurinia Pharmaceuticals in a research note on Thursday, June 30th. They issued a “buy” rating and a $7.00 target price for the company. Canaccord Genuity reiterated a “buy” rating on shares of Aurinia Pharmaceuticals in a research note on Thursday, May 12th. Finally, Zacks Investment Research upgraded shares of Aurinia Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, May 24th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $7.15.

The company’s market capitalization is $111.71 million. The company has a 50 day moving average price of $2.92 and a 200-day moving average price of $2.67.

Aurinia Pharmaceuticals Inc (Aurinia) is a Canada-based is a clinical stage pharmaceutical company. The Company is focused on the development of its therapeutic immunomodulating drug candidate, voclosporin, which is a calcineurin inhibitor (CNI). Voclosporin is an oral drug, administered twice daily.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.